Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Clive S. Zent, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Betsy R. LaPlant, Thomas Elmer Witzig, Stephen Maxted Ansell, George J. Weiner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% confidence interval [CI]: 9.7, 32.1) and eight patients were retreated (median 35.3 months, 95% CI: 17.9, not reached). We conclude that PGG beta glucan, alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate.

Original languageEnglish (US)
Pages (from-to)2373-2378
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number8
DOIs
StatePublished - Aug 3 2015

Fingerprint

beta-Glucans
B-Cell Chronic Lymphocytic Leukemia
Confidence Intervals
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Glucans
Saccharomyces cerevisiae
Immune System
Biomarkers
alemtuzumab
Rituximab
poly-1-6-glucopyranosyl-1-3-glucopyranose glucan

Keywords

  • alemtuzumab
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma
  • CLL
  • high risk
  • PGG beta glucan
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. / Zent, Clive S.; Call, Timothy G.; Bowen, Deborah A.; Conte, Michael J.; LaPlant, Betsy R.; Witzig, Thomas Elmer; Ansell, Stephen Maxted; Weiner, George J.

In: Leukemia and Lymphoma, Vol. 56, No. 8, 03.08.2015, p. 2373-2378.

Research output: Contribution to journalArticle

@article{915a8d42715446259bbb60ef8dd719e0,
title = "Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates",
abstract = "Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95{\%}) patients responded to treatment with 13 (65{\%}) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95{\%} confidence interval [CI]: 9.7, 32.1) and eight patients were retreated (median 35.3 months, 95{\%} CI: 17.9, not reached). We conclude that PGG beta glucan, alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate.",
keywords = "alemtuzumab, Chronic lymphocytic leukemia/small lymphocytic lymphoma, CLL, high risk, PGG beta glucan, rituximab",
author = "Zent, {Clive S.} and Call, {Timothy G.} and Bowen, {Deborah A.} and Conte, {Michael J.} and LaPlant, {Betsy R.} and Witzig, {Thomas Elmer} and Ansell, {Stephen Maxted} and Weiner, {George J.}",
year = "2015",
month = "8",
day = "3",
doi = "10.3109/10428194.2015.1016932",
language = "English (US)",
volume = "56",
pages = "2373--2378",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

AU - Zent, Clive S.

AU - Call, Timothy G.

AU - Bowen, Deborah A.

AU - Conte, Michael J.

AU - LaPlant, Betsy R.

AU - Witzig, Thomas Elmer

AU - Ansell, Stephen Maxted

AU - Weiner, George J.

PY - 2015/8/3

Y1 - 2015/8/3

N2 - Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% confidence interval [CI]: 9.7, 32.1) and eight patients were retreated (median 35.3 months, 95% CI: 17.9, not reached). We conclude that PGG beta glucan, alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate.

AB - Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% confidence interval [CI]: 9.7, 32.1) and eight patients were retreated (median 35.3 months, 95% CI: 17.9, not reached). We conclude that PGG beta glucan, alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate.

KW - alemtuzumab

KW - Chronic lymphocytic leukemia/small lymphocytic lymphoma

KW - CLL

KW - high risk

KW - PGG beta glucan

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84943379790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943379790&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1016932

DO - 10.3109/10428194.2015.1016932

M3 - Article

C2 - 25676035

AN - SCOPUS:84943379790

VL - 56

SP - 2373

EP - 2378

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -